<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030430</url>
  </required_header>
  <id_info>
    <org_study_id>BAT-1706-001</org_study_id>
    <nct_id>NCT03030430</nct_id>
  </id_info>
  <brief_title>Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects</brief_title>
  <official_title>Randomized, Double-blind, Single-dose, 3-arm Parallel Design Comparative Pharmacokinetic(PK) and Safety Study of BAT1706 Versus European Union(EU)-Sourced Avastin® and United State (US)-Sourced Avastin® Administered in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio-Thera Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio-Thera Solutions</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish PK similarity in the treatment of BAT1706 and&#xD;
      comparators.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, randomized, double-blind, single-dose, 3-arm parallel group study to&#xD;
      compare the PK, and to evaluate the safety, tolerability and immunogenicity, of BAT1706,&#xD;
      EU-Avastin and US-Avastin after a single IV infusion in healthy adult male subjects.&#xD;
&#xD;
      A total of 129 healthy male subjects who meet the required entry criteria will be randomly&#xD;
      assigned to one of three treatment groups in a 1:1:1 ratio to receive a single IV infusion of&#xD;
      either BAT1706, EU-Avastin or US-Avastin. A total of 117 evaluable subjects are required.&#xD;
&#xD;
      Initially, subjects will be administered the study drug in staggered groups; the first group&#xD;
      will comprise 3 subjects, the second group 6 subjects and the third group 9 subjects. Within&#xD;
      each group subjects will be randomized to ensure equal numbers of subjects receive each of&#xD;
      the three treatments.&#xD;
&#xD;
      There will be at least 48 hours between administrations of study drug to each group. Prior to&#xD;
      administration of study drug to the next group, the safety and tolerability findings of the&#xD;
      preceding group will be reviewed by the Principal Investigator. The next group will be dosed&#xD;
      provided there are no serious or unexpected drug-related safety issues. Each subject will be&#xD;
      required to remain in the clinical center for 48 hours after dosing for safety evaluation.&#xD;
&#xD;
      After the first 3 groups have been evaluated, the Principal Investigator will decide whether&#xD;
      to proceed with continuous enrolment according to the clinical center capability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2016</start_date>
  <completion_date type="Actual">June 28, 2017</completion_date>
  <primary_completion_date type="Actual">May 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under curve (AUC)0~∞</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>BAT1706</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT1706 injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-sourced Avastin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU-sourced Avastin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-sourced Avastin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US-sourced Avastin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BAT1706 injection</intervention_name>
    <description>1mg/kg, IV on day 1</description>
    <arm_group_label>BAT1706</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU-sourced Avastin</intervention_name>
    <description>1mg/kg, IV on day 1</description>
    <arm_group_label>EU-sourced Avastin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US-sourced Avastin</intervention_name>
    <description>1mg/kg, IV on day 1</description>
    <arm_group_label>US-sourced Avastin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males aged 18 to 50 years inclusive and body weight 65 to 100kg.&#xD;
&#xD;
          2. Subjects who are healthy as determined by pre-study medical history, physical&#xD;
             examination, vital signs and 12 ECG.&#xD;
&#xD;
          3. Subjects whose clinical laboratory test results are normal, or where outside the&#xD;
             reference range are judged as not clinical relevant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a history of and/or current clinically significant gastrointestinal, renal,&#xD;
             hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric&#xD;
             or allergic disease excluding mild asymptomatic seasonal allergies.&#xD;
&#xD;
          2. Subject with a psychiatric disorder or considered unsuitable for inclusion by the&#xD;
             investigator.&#xD;
&#xD;
          3. History or current clinically significant, excluding mild asymptomatic seasonal&#xD;
             allergies, hypersensitivity or allergic reactions including known or suspected drug&#xD;
             hypersensitivity to any component of the study drug formulations or comparable drugs.&#xD;
&#xD;
          4. Any biological drug within 3 months or monoclonal antibodies within 9 months of study&#xD;
             drug administration.&#xD;
&#xD;
          5. Intake of herbal remedies within 14 days prior to study drug administration.&#xD;
&#xD;
          6. History of alcohol abuse or a positive alcohol test on screening or admission to the&#xD;
             clinical center.&#xD;
&#xD;
          7. Any persons who are:an employee of the Principal Investigator, clinical center,&#xD;
             Clinical Research Organization (CRO) or Sponsor;a relative of an employee of the&#xD;
             clinical center, the Investigators, CRO or the Sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Wynne, Medical Doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust Ltd (CCST)</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2017</study_first_posted>
  <last_update_submitted>July 27, 2018</last_update_submitted>
  <last_update_submitted_qc>July 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 5, 2020</submitted>
    <returned>December 3, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

